References
- FriedmanNDKormanTMFairleyCKFranklinJCSpelmanDWBacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodesJ Infect2002451475312217732
- BrookeJSStenotrophomonas maltophilia: an emerging global opportunistic pathogenClin Microbiol Rev201225124122232370
- JangTNWangFDWangLSLiuCYLiuIMXanthomonas maltophilia bacteremia: an analysis of 32 casesJournal of the Formosan Medical Association19929112117011761363639
- VictorMAArpiMBruunBJonssonVHansenMMXanthomonas maltophilia bacteremia in immunocompromised hematological patientsScand J Infect Dis19942621631708036472
- BushKImproving known classes of antibiotics: an optimistic approach for the futureCurr Opin Pharmacol201212552753422748801
- BoucherHWTalbotGHBenjaminDKJrInfectious Diseases Society of America10 × ‘20 Progress – development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of AmericaClin Infect Dis201356121685169423599308
- MichalopoulosASLivaditisIGGougoutasVThe revival of fosfomycinInt J Infect Dis20111511e732e73921945848
- DhariwalAKTulluMSColistin: re-emergence of the ‘forgotten’ antimicrobial agentJ Postgrad Med201359320821524029199
- CarmineAABrogdenRNHeelRCRomankiewiczJASpeightTMAveryGSMoxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic useDrugs19832642793336354685
- AkovaMBonfiglioGLivermoreDMSusceptibility to beta-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 beta-lactamasesJ Med Microbiol19913542082131941990
- Lecso-BornetMPierreJSarkis-KaramDLuberaSBergogne-BerezinESusceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitroAntimicrob Agents Chemother19923636696711622183
- GulmezDHascelikGStenotrophomonas maltophilia: antimicrobial resistance and molecular typing of an emerging pathogen in a Turkish university hospitalClin Microbiol Infect2005111188088616216102
- LaiCHChiCYChenHPClinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremiaJ Microbiol Immunol Infect200437635035815599467
- JonesRNSaderHSBeachMLContemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997–2001)Int J Antimicrob Agents200322655155614659650
- MuderRROptimizing therapy for Stenotrophomonas maltophiliaSemin Respir Crit Care Med200728667267718095231
- ChoSYKangCIKimJCan levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?Antimicrob Agents Chemother201458158158324126583
- WangYLScipioneMRDubrovskayaYPapadopoulosJMonotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infectionsAntimicrob Agents Chemother201458117618224145530